Medicine Information

Generating Pharmaceutical Sales before Marketing Authorization


When a patient has a serious illness and there is no approved drug available, the physician may want to try one which has not been authorized for marketing by national health authorities but has shown promise in clinical trials. European Named Patient Programs, like US compassionate use programs, offer physicians access to pharmaceuticals which have not yet been licensed. However, there is one important difference: in Europe an unlicensed drug can be reimbursed. This presents drug-makers with an opportunity to generate revenues while development is still in-progress.

Significant Revenues Are Possible

The additional revenues can be considerable. For example, Pharmion, a US based company focusing on Oncology and Hematology reported dramatic increases in its Thalidomide sales from $1.9 million in 2Q '03 to $15.3 million in 2Q '04, primarily due to named patient sales in Europe for Multiple Myeloma. Thalidomide sales accounted for approximately 75% of Pharmion's total revenues for the first half of 2004, according to company sources, and were generated while the product awaits marketing approval for this indication. Before receiving European Marketing Approval, Shire's Argylin® for essential thrombocythaemia generated about 5% of its total sales from its European named patient program.

Though thalidomide and Agrylin were licensed in the USA for some indications, pharmaceutical companies do set-up named patient programs and receive full reimbursement for drugs that are not licensed for any indication in any market. Examples include: Insmed's SomatoKine® authorized for named patient use for Primary Lateral Sclerosis, Growth Hormone Insensitivity Syndrome (GHIS) and Severe Insulin Resistance and Protherics' ViperaTAb? authorized for named patient use for adder snake bites.

Other Benefits of Named Patient Programs

A named patient program can speed uptake after official launch. Physicians, who have had experience before launch, via clinical trials or named patient programs, often become early adopters and references for other physicians once the drug is freely circulating.

Named patient programs, like US compassionate use programs, can increase good-will toward the company because they simplify the process of gaining access for patients in critical need. Smaller companies often can not afford the administrative time and costs of shipping drugs around the world before launch. This can lead to frustration and resentment towards a company that many physicians will remember long after a drug is officially on the market. Creating a formal channel eliminates the unfortunate need of denying requests and risking ill-will later.

A named patient program should be considered an important part of a pre-launch program. It increases awareness to a pharmaceutical's existence, creates excitement, generates good-will and speeds penetration of the product after launch.

Frequent Communication is Necessary

If one of the objectives is to generate revenues, setting up a named patient program is just the beginning. In order to achieve success, physicians need to be aware of the product and what they need to do to get it. Typical methods of informing physicians, such as sales rep visits and ads, may not be appropriate because a license is necessary to market a drug. While physicians are used to simply writing a prescription and being done with it, named patient programs require paper-work that some find tedious. Therefore the company needs to create an appropriate communication plan and work closely with the targeted medical community to keep them informed and simplify the process.

Issues to Consider

You have decided to make a named patient program part of your pre-marketing plan, what now?

? Administration: Do you "go it alone" or work with a company that is experienced at administering named patient programs?

There are several experienced organizations that can assist your company by gaining approval, setting-up the program, doing administration and taking care of physical distribution. If your organization is well resourced and has a pipe-line of products that will require named patient programs, it might be worthwhile acquiring the expertise internally. However, if you have few appropriate products or a stream-lined organization, it is probably best to consider outsourcing.

? Communication: You've set up the program, how do you optimize it?

If you do not have an experienced European marketing group, an organization that is familiar in sales and marketing of pharmaceuticals in Europe can help you to maximize participation in the named patient program. A communication plan, if properly developed and implemented can increase product awareness, but communication concerning an unlicensed product must be done appropriately. This plan should ensure that your entire target group:

? Is fully aware of the product AND the program

? Knows what needs to be done to take advantage of the program

? Has an advocate available to guide them through the process

The Author, Dr Gene Emmer, is President of Med Services Europe B.V., a European-based consultancy focused on Sales, Marketing and Business Development of Pharmaceutical, Diagnostic and Medical Products. http://www.MedServicesEurope.com +31648566707


MORE RESOURCES:
This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news


#MeToo in medicine: Women, harassed in hospitals and operating ...
NBCNews.com
In a months-long investigation, NBC News spoke with nearly a dozen women and experts who described widespread misconduct in hospitals and health care.

and more »


New York Post

Venezuelans with transplants live in fear as medicine runs out
New York Post
After years leading normal lives, they now live in fear as Venezuela's economic collapse under President Nicolas Maduro has left the once-prosperous OPEC nation unable to purchase sufficient foreign medicine or produce enough of its own. Some 31 ...

and more »


גלובס

Globes English - Vaica reminds patients to take medicine - גלובס
גלובס
The Israeli company adapts its reminders to the patient's age and the type of medicine.

and more »


The Courier-Journal

University of Louisville takes its medicine and starts healing process | Tim Sullivan
The Courier-Journal
There's never a wrong time to do the right thing. There's rarely a point where a public institution is better served by technicalities than truth. The University of Louisville has paid a high price for coming clean with its dirty laundry, with self ...
Louisville men's basketball must vacate wins and pay fine | NCAA.org - The Official Site of the NCAANCAA.org
NCAA denies Louisville's appeal, rules Cardinals must vacate 2013 national titleESPN

all 232 news articles »


OncLive

Gastrointestinal Cancers Entering Age of Precision Medicine
OncLive
He: We had 4 excellent faculty who talked about the updates to pancreatic and hepatobiliary cancer treatment, treatment of neuroendocrine tumors (NETs) of the GI tract, and precision medicine. Molecular profiling has been identified as a very important ...



VentureBeat

4 ways AI could help shape the future of medicine
VentureBeat
At times, progress occurs so quickly that it's difficult to separate science fiction from real life. Just five decades ago, computers were massive, unwieldy machines running on punch cards and primitive circuits. Today, a single smartphone has more ...



UCD School of Medicine scores high in NIH research funding
Davis Enterprise
For the first time, UC Davis School of Medicine has ranked in the top 20 percent of institutions in the country for research funding from the National Institutes of Health. “The proportion of NIH funding is an important measure of research excellence ...

and more »


Seeking Alpha

Loxo Oncology Will Fulfill The Promise Of Precision Medicine
Seeking Alpha
Based in Stamford, Connecticut, Loxo Oncology is dedicated to developing precision medicines against genetically defined cancers. Its highly selective drugs in the pipeline will shift the paradigm of cancer treatment from the traditional "one-size-fits ...
Financial Newsletter - ZacksZacks
Loxo Oncology, Inc. - LOXO - Stock Price Today - ZacksZacks
Loxo Oncology CS (LOXO) Stocks Latest Headlines - Barchart.comBarchart.com

all 15 news articles »


NBCNews.com

For-profit medicine incentivizes overmedicating our elderly rather than caring for them
NBCNews.com
Michelle Chen For-profit medicine incentivizes overmedicating our elderly rather than caring for them. Denying seniors humane care deprives all of us of the right to age with dignity. Feb.20.2018 / 1:25 AM ET. We must reject a culture of medicalizing ...



Centralia Chronicle

Chehalis Family Medicine Residency Program Aims to Improve Quality of Care in Rural Areas
Centralia Chronicle
For the past three years, the Chehalis Family Medicine clinic has been operating a rural residency program in an effort to improve the standards of care received by its patients. In rural areas, which includes the vast majority of Southwest Washington ...


Google News

home | site map | Dr. Thad Thomas
© 2006